Derivation of the Kelvin Equation

从液滴平衡条件推导出严格意义的Kelvin方程,验证了其在宏观尺度可以转化为经典形式.利用Tolman方程,在考虑表面张力与曲率半径关系的条件下,给出在液体压缩性可忽略时,饱和蒸气压、蒸气密度、蒸气摩尔体积和曲率半径等关系;液体压缩性不可忽略时,得出以等温压缩系数和Tolman长度表示的饱和蒸气压与液滴半径的关系

On the equilibrium conditions for a spherical-cap liquid drop on a solid surface-Also comments on "Thermodynamic mechanism for the condensation of liquid drops on the condenser surface" etc.

对于第一类液滴(尺度远大于界面层的厚度),无论是远离固体壁面的液体球或附着在壁面上的球冠,其内外压力差(简称"附加压力")均适用经典Laplace公式,并且特别对球冠情况给出了一种新的整体性证明.还澄清有关争论:指出[曹治党、郭愚1999物理学报481823]一文对附壁面第一类液体球冠所推导出的附加压力与接触角有关的公式是错误的,而[闵敬春2002物理学报512730]是正确的

空间智能软体机械臂动力学建模与控制

空间智能软体机械臂因其结构轻巧、灵活可变、可折叠收缩等特性，在航天器在轨服务任务中，将具有广阔的应用前景。首先提出了一种全向驱动的模块化软体机械臂设计方案，利用刚柔耦合动力学理论建立了气控驱动的软体机械臂动力学模型，基于深度回归卷积神经网络理论建立了空间非合作目标检测与识别算法，为空间软体机械臂智能控制奠定了技术基础。进一步地，设计并研制了软体机械臂地面原理样机及其试验系统，通过地面试验，对软体机械臂的自主运动控制和识别算法进行了初步验证

光合电子流对光响应的机理模型及其应用

光合电子流对光响应的机理可以揭示植物光合电子流与光强、植物捕光色素分子物理特性之间的关系。该文讨论了光合电子流对光响应的机理模型的特性以及捕光色素分子的物理性质,并利用此模型拟合了山莴苣(Lagedium sibiricum)、一年蓬(Erigeron annuus)和紫菀(Aster tataricus)的光合电子流对光响应的曲线。由此模型不仅可以得到植物的最大光合电子流、饱和光强、初始斜率等参数,还可以获得捕光色素分子有效光能吸收截面和处于最低激发态的捕光色素分子数对光的响应关系。结果表明:随光强的增加,山莴苣的捕光色素分子的有效光能吸收截面下降最快,紫苑的下降速度最慢;山莴苣处于最低激发态的捕光色素分子数增长速度最快,紫苑的增长速度最小。捕光色素分子的有效光能吸收截面随光强增加而下降、处于最低激发态的捕光色素分子数随光强增加而增加的特性将减少其光能的吸收和激子的传递,因而有利于减少强光对植物产生的光伤害

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies